Overview

Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This is a multicentre phase I/II trial looking at the combination of romidepsin and carfilzomib. The aim of the phase I part is to determine the maximum tolerated dose (MTD) of the combination. This part will recruit up to 27 patients, plus possibly an additional 3 patients at the MTD. The aim of the phase II part is to assess the activity of the combination at the maximum tolerated dose in 28 patients (including at least 6 patients treated at the MTD from phase I). Patients will receive 8 cycles of romidepsin with carfilzomib and response will be assessed every second cycle. Patients will be followed up for progression and survival until the end of the trial.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Birmingham

Collaborators:

Amgen
Bloodwise
Celgene

Treatments:

Romidepsin